

Financial news for LPTN dated on 2016-12-22: 12 Biggest Mid-Day Losers For Thursday

Financial news for LPTN dated on 2016-09-09: Mid-Day Market Update: Dow Down Over 200 Points; Finisar Shares Surge Following Strong Results

Financial news for LPTN dated on 2016-09-09: Mid-Morning Market Update: Markets Open Lower; Kroger Lowers FY Forecast

Financial news for LPTN dated on 2016-09-08: Benzinga's M&A Chatter for Thursday September 8, 2016

Financial news for LPTN dated on 2016-09-08: Lpath Shares Indicated Up 37% In Post-Market Trade At \$3.50/Share

Financial news for LPTN dated on 2016-09-08: Lpath Shares to Resume Trade at 4:35 p.m. EDT

Financial news for LPTN dated on 2016-09-08: UPDATE: Lpath Will Issue Stock Or Rights To Acquire Its Stock To Apollo Security Holders; Apollo Will Become Majority Owners Of Lpath With ~95.8% Of Company And \$29M Investment

Financial news for LPTN dated on 2016-09-08: Apollo Endosurgery, Lpath Sign Merger Agreement

Financial news for LPTN dated on 2016-09-08: Lpath Shares Halted News Pending

Financial news for LPTN dated on 2016-08-23: 15 Biggest Mid-Day Losers For Tuesday

Financial news for LPTN dated on 2016-08-22: Lpath Files S-3 For \$10M Mixed Shelf Offering

Financial news for LPTN dated on 2016-08-17: Lpath Spikes to High of \$2.15 on Volume

Financial news for LPTN dated on 2016-06-22: Lpath Sells off to Low of \$2.17 on Vol

Financial news for LPTN dated on 2016-06-20: Mid-Afternoon Market Update: Yelp Shares Gain Following Analyst Upgrade; Cypress Semiconductor Shares Drop

Financial news for LPTN dated on 2016-06-20: 10 Biggest Mid-Day Gainers For Monday

Financial news for LPTN dated on 2016-06-20: Mid-Day Market Update: Crude Oil Rises 2.5%; Epizyme Shares Drop

Financial news for LPTN dated on 2016-06-20: Mid-Morning Market Update: Markets Open Higher; Icahn Enterprises Raises Offer For Federal Mogul

Financial news for LPTN dated on 2016-06-20: Lpath Awarded \$1.45M 2-Year Grant For Traumatic Brain Injury Pain Study

Financial news for LPTN dated on 2016-06-09: Lpath Reveals 1-For-14 Reverse Stock Split

Financial news for LPTN dated on 2016-06-09: Lpath Reports 1-for-14 Reverse Split

Financial news for LPTN dated on 2016-04-19: Lpath Shows Acceptable Safety & Tolerability Doses As High As 20mg/kg With A Favorable Pharmacokinetic Profile

Financial news for LPTN dated on 2015-09-29: Lpath Names Gary Atkinson Interim CEO

Financial news for LPTN dated on 2015-09-15: Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab

Financial news for LPTN dated on 2015-07-23: Lpath Offers Plan for Commencement of Lpathomaba Trial

Financial news for LPTN dated on 2015-05-20: Stocks Hitting 52-Week Lows

Financial news for LPTN dated on 2015-05-20: Morning Market Losers

Financial news for LPTN dated on 2015-05-20: UPDATE: Lpath Says Study Did Not Meet Primary or Key Secondary Endpoints; Company to Undergo Corporate Restructuring

Financial news for LPTN dated on 2015-05-20: Shares of Lpath Halted Following Release of News

Financial news for LPTN dated on 2015-05-20: Lpath Announces Results for iSONEP in Patients with Wet Age-related Macular Degeneration

Financial news for LPTN dated on 2015-03-25: Morning Market Losers

Financial news for LPTN dated on 2015-03-24: Lpath Reports Phase 2a Study Results for ASONEP in Renal Cell Carcinoma

Financial news for LPTN dated on 2015-03-11: Lpath To Submit More Data For Lpathomab's New Drug Application

Financial news for LPTN dated on 2015-02-02: Lpath Submits IND Application to FDA for Lpathomab for Neuropathic Pain

Financial news for LPTN dated on 2014-12-03: Morning Market Movers

Financial news for LPTN dated on 2014-12-02: Lpath Completes Enrollment In Its Phase 2 Clinical Trial Of iSONEP

Financial news for LPTN dated on 2014-11-04: Lpath Announces Departure Of CEO Scott Pancoast; Michael Lack To Interim CEO

Financial news for LPTN dated on 2014-10-20: Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs

Financial news for LPTN dated on 2014-09-29: Lpath Announces Closing of \$12.5M Registered Direct Offering

Financial news for LPTN dated on 2014-09-19: Lpath Announces \$12.5M Registered Direct Offering

Financial news for LPTN dated on 2014-08-11: Morning Market Losers

Financial news for LPTN dated on 2014-07-24: Lpath Says Phase 2a Trial Favorable So Far

Financial news for LPTN dated on 2014-04-16: UPDATE: Lpath Shares Rise 10% Following Initiation by Canaccord Genuity with Buy Rating and \$17.00 PT

Financial news for LPTN dated on 2014-04-16: UPDATE: Canaccord Genuity Initiates Coverage on Lpath on iSONEP Potential

Financial news for LPTN dated on 2014-03-18: LPATH Files Prospectus for Up to \$23M in Shares

Financial news for LPTN dated on 2014-03-05: New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models

Financial news for LPTN dated on 2014-01-22: Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

Financial news for LPTN dated on 2013-10-15: UPDATE: JMP Securities Initiates Coverage on Lpath on Potential of iSONEP and ASONEP

Financial news for LPTN dated on 2013-10-08: Lpath Says Pfizer Notice Includes Option for iSONEP License

Financial news for LPTN dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)

Financial news for LPTN dated on 2013-03-22: Lpath Says Wins Key European, US Patents Related to Asonep

Financial news for LPTN dated on 2012-12-27: UPDATE: Summer Street Initiates Lpath Incorporated at Buy on Valuation

Financial news for LPTN dated on 2012-12-27: Summer Street Research Initiates Lpath Incorporated at Buy, \$18 PT

Financial news for LPTN dated on 2012-12-14: Morning Market Losers

Financial news for LPTN dated on 2012-12-14: Lpath Shares Resume, Down ~15%

Financial news for LPTN dated on 2012-12-14: Lpath Shares to Resume at 9:45AM EST

Financial news for LPTN dated on 2012-12-14: Lpath Prices 2.4M Shares at \$5/Share

Financial news for LPTN dated on 2012-12-14: Lpath Halted News Pending

Financial news for LPTN dated on 2012-12-13: Lpath Announces Proposed Public Offering of Common Stock

Financial news for LPTN dated on 2012-12-11: Lpath, Pfizer Amended Pact to Reflect

Discontinuing Pedigree Trial, Will Focus on Nexus Trial

Financial news for LPTN dated on 2012-12-05: Lpath Receives Key European Patent Related to Isonop Drug Program

Financial news for LPTN dated on 2012-10-10: Lpath: Things Looking Brighter for Bioactive Lipid-Targeted Therapeutics Leader

Financial news for LPTN dated on 2012-03-01: Rumors Sending Speculators Back for More Shares of LPath

Financial news for LPTN dated on 2012-01-26: Scorecard and New Picks: Technical Value Fishing Under \$5

Financial news for LPTN dated on 2011-11-18: Lpath Gets \$8 Price Target and Attention as Buy-Out Candidate

Financial news for LPTN dated on 2011-06-09: Lpath Granted 22nd Patent Related to Lipidomics-Based Drug Development Program